- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01323465
Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex
April 7, 2023 updated by: Jazz Pharmaceuticals
A Phase I, Open-label, Randomised, Crossover Study in 3 Parallel Groups to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex in Healthy Volunteers
Study to assess the effect of rifampicin, ketoconazole and omeprazole on the pharmacokinetics of a single dose of Sativex and to evaluate the safety of Sativex when given in combination with these other drugs.
Study Overview
Status
Completed
Conditions
Detailed Description
An open-label, randomised, crossover, drug interaction study.
Subjects were divided into three groups and within each group, subjects were randomised to one of two treatment sequences.
Subjects received 4 sprays of Sativex alongside either doses of rifampicin, ketoconazole or omeprazole.
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
London, United Kingdom, SE1 1YR
- Guy's Drug Research Unit, Quintiles Ltd.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Healthy male subjects between 18 and 45 years of age (inclusive).
- Subjects body mass index was between 18-30 kg/m2 (inclusive) as calculated by: Weight (kg)/height (m2).
- No clinically significant abnormal findings on the physical examination, ECG, medical history, or clinical laboratory results during screening.
- Subjects were to, in the opinion of the investigator, have no clinically significant abnormal findings of renal and hepatic function as determined by serum creatinine, total bilirubin, and transaminase levels.
- Subjects were to be non-users of tobacco products (minimum of 6 months prior to the start of the study).
- Subjects were to have a negative screen for HIV I and II, HBsAg. and antibody to hepatitis C.
- Subjects were to have a negative urine screen for alcohol, drugs of abuse (screening only), and cotinine.
- Subjects were to use an appropriate barrier method of contraception (condom and spermicide) in addition to having their female partner use another form of barrier contraception (e.g. female condom or occlusive cap [diaphragm or cervical vault/caps] with spermicide) during the study and for 3 months following administration of the study drug.
- Subjects were to be able to comply with the protocol and the restrictions and the assessments therein.
- Subjects were to give voluntary written informed consent to participate in the trial.
Exclusion Criteria:
- Subjects were not to have a history or presence of significant cardiovascular, pulmonary, hepatic, renal, haematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease.
- Subjects were not to have any history or presence of family history of schizophrenia, other psychotic illness, severe personality disorder, depression, or other significant psychiatric disorder.
- Subjects were not to have a postural drop of 20 mmHG or more in systolic blood pressure at screening.
- Subjects were not to have participated in a previous clinical trial within 90 days prior to study initiation.
- Subjects were not to have donated plasma within 90 days prior to study initiation.
- Subjects were not to have donated blood within 90 days prior to study initiation.
- Subjects were not to have had an abnormal diet or substantial changes in eating habits within 30 days prior to study initiation.
- Subjects were not to have had treatment with any known enzyme-altering agents (barbiturates, phenothiazines, cimetidine etc.) within 30 days prior to or during the study.
- Subjects were to have no history of known hypersensitivity or idiosyncratic reaction to the study drugs or related compounds.
- Subjects were not to use any prescription medication within 14 days prior to or during the study.
- Subjects were not to use any over-the-counter medication within 7 days prior to or during the study.
- Subjects were not to have a history of alcohol or drug abuse within 2 years prior to the study (subjects with a history of previous use of cannabis were not excluded unless they had used cannabis or cannabinoid based medicine within 30 days prior to study drug administration or were unwilling to abstain for the duration of the study).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sequence 1A
Sativex and rifampicin
|
Single dose of 4 sprays Sativex on Day 1, Rifampicin 2 x 300 mg capsules on Days 2-10, Sativex dose of 4 sprays and rifampicin 2 x 300 mg capsules on Day 11.
Rifampicin 2 x 300 mg capsules on Days 1-9, Sativex x 4 sprays and rifampicin 2 x 300 mg capsules on Day 10, Single dose of Sativex 4 sprays on Day 18.
|
Experimental: Sequence 1B
Sativex and rifampicin
|
Single dose of 4 sprays Sativex on Day 1, Rifampicin 2 x 300 mg capsules on Days 2-10, Sativex dose of 4 sprays and rifampicin 2 x 300 mg capsules on Day 11.
Rifampicin 2 x 300 mg capsules on Days 1-9, Sativex x 4 sprays and rifampicin 2 x 300 mg capsules on Day 10, Single dose of Sativex 4 sprays on Day 18.
|
Experimental: Sequence 2C
Sativex and ketoconazole
|
Single dose of 4 sprays Sativex on Day 1, ketoconazole 2 x 200 mg tablets on Days 2-5, Sativex x 4 sprays and ketoconazole 2 x 200mg on Day 6.
Ketoconazole 2 x 200 mg tablets on Days 1-4, Sativex x 4 sprays and ketoconazole 2 x 200 mg tablets on Day 5, Single dose of 4 sprays Sativex on Day 9.
|
Experimental: Sequence 2D
Sativex and ketoconazole
|
Single dose of 4 sprays Sativex on Day 1, ketoconazole 2 x 200 mg tablets on Days 2-5, Sativex x 4 sprays and ketoconazole 2 x 200mg on Day 6.
Ketoconazole 2 x 200 mg tablets on Days 1-4, Sativex x 4 sprays and ketoconazole 2 x 200 mg tablets on Day 5, Single dose of 4 sprays Sativex on Day 9.
|
Experimental: Sequence 3E
Sativex and omeprazole
|
Single dose of 4 sprays of Sativex on Day 1 Omeprazole 2 x 20 mg on Days 2-6.
Sativex x 4 sprays and omeprazole 2 x 20 mg on Day 9.
Omeprazole 2 x 20 mg on Days 1-5, Sativex x 4 sprays and omeprazole 2 x 20 mg on Day 6, Single dose of 4 sprays Sativex on Day 9.
|
Experimental: Sequence 3F
Sativex and omeprazole
|
Single dose of 4 sprays of Sativex on Day 1 Omeprazole 2 x 20 mg on Days 2-6.
Sativex x 4 sprays and omeprazole 2 x 20 mg on Day 9.
Omeprazole 2 x 20 mg on Days 1-5, Sativex x 4 sprays and omeprazole 2 x 20 mg on Day 6, Single dose of 4 sprays Sativex on Day 9.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetic analysis - Cmax of Sativex® alone and of Sativex® with concomitant administration of rifampicin, ketoconazole, and omeprazole
Time Frame: Up to Day 8
|
Up to Day 8
|
Pharmacokinetic analysis - AUC(0-t) of Sativex® alone and of Sativex® with concomitant administration of rifampicin, ketoconazole, and omeprazole
Time Frame: Up to day 8
|
Up to day 8
|
Pharmacokinetic analysis - AUC(0-inf) of Sativex® alone and of Sativex® with concomitant administration of rifampicin, ketoconazole, and omeprazole
Time Frame: Up to Day 8
|
Up to Day 8
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse Events
Time Frame: Up to follow up, Day 14
|
Up to follow up, Day 14
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2008
Primary Completion (Actual)
March 1, 2008
Study Completion (Actual)
March 1, 2008
Study Registration Dates
First Submitted
March 23, 2011
First Submitted That Met QC Criteria
March 24, 2011
First Posted (Estimate)
March 25, 2011
Study Record Updates
Last Update Posted (Actual)
April 10, 2023
Last Update Submitted That Met QC Criteria
April 7, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Peripheral Nervous System Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Gastrointestinal Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Anti-Bacterial Agents
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Leprostatic Agents
- Hormone Antagonists
- Cytochrome P-450 Enzyme Inducers
- Antifungal Agents
- Steroid Synthesis Inhibitors
- Anti-Ulcer Agents
- Proton Pump Inhibitors
- Cytochrome P-450 CYP3A Inducers
- Antitubercular Agents
- 14-alpha Demethylase Inhibitors
- Antibiotics, Antitubercular
- Cytochrome P-450 CYP2B6 Inducers
- Cytochrome P-450 CYP2C8 Inducers
- Cytochrome P-450 CYP2C19 Inducers
- Cytochrome P-450 CYP2C9 Inducers
- Ketoconazole
- Rifampin
- Omeprazole
- Nabiximols
Other Study ID Numbers
- GWCP0602
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4
-
Centre Hospitalier Universitaire DijonCompletedPersons Who Have Experienced a Sudden Uncontrolled Fall in the Absence of Outside Factors in the 6 Months Preceding the ConsultationFrance
-
Virginia Commonwealth UniversityCompletedBiomarkers of Ischemia: Xanthine, Hypoxanthine and Inosine Levels During Carotid Stenting ProceduresIdentify the Presence of a Marker of Ischemia/Hypoperfusion of the Brain Via Peripheral Blood | Ischemia/Hypoperfusion of BrainUnited States
-
Egalet LtdCompletedAssess Pharmacokinetics of Ketorolac Tromethamine Intranasal and Assess Effects of a Oxymetazoline Hydrochloride on the PK of Ketorolac TromethamineUnited Kingdom
-
University of BolognaCompletedThe Presence of Horizontal and Vertical Alveolar Defects in Both Jaws, Inadequate for the Placement of at Least Two Fixtures, Even ≤6 mm Long Ones
-
Poitiers University HospitalCompletedIdentification of the Mother or Fetus Contamination by SARS Cov-2 | Research the Presence of Viruses at Different Sites of the Mother and the Fetus or Father | The Survey Builds on a Network Work Already Organized Around the CPDPN of Poitou-Charentes | Analysis Laboratories of the Poitiers...France
-
Zhejiang Cancer HospitalUnknownEvaluation of the Value of Mammaprint Test Gene Variation in the Prediction of Neoadjuvant Chemotherapy for Breast CancerChina
-
NovartisCompletedScreening for the Presence of HIV-1, RNA and HBV DNA in Blood DonationsTaiwan
-
InvestigatorUrologyIBSALInstituto de Investigación Biomédica de SalamancaUnknownEstablish the Efficacy Between the Four Schemes in Terms of the Aggressiveness of the Tumors According to the Gleason Classification | Establish the Efficacy Between the Four Schemes in Terms of Morbidity Associated With the Technique | Establish the Efficacy Between the Four Schemes... and other conditionsSpain
-
Second Affiliated Hospital, School of Medicine,...CompletedThe Fixation Mainly Plays a Firm Role in the Tracheal Intubation and Reduces the Occurrence of ComplicationsChina
-
UNC Lineberger Comprehensive Cancer CenterUNC Translational and Clinical Sciences (Tracs)CompletedA History of Radiation Therapy for a Tumor in the Vicinity of the Retina(s)United States
Clinical Trials on Sativex and rifampicin
-
King's College LondonSouth London and Maudsley NHS Foundation TrustCompletedAttention Deficit Hyperactivity Disorder (ADHD)United Kingdom
-
AbbottRecruiting
-
Annina VischerNot yet recruitingHypertension | Blood Pressure, High
-
University of Mississippi Medical CenterTerminatedBlood Pressure | GoutUnited States
-
Ain Shams UniversityCompletedEndothelial Dysfunction | Endstage Renal Disease
-
Mary LynchCompleted
-
S. Andrea HospitalUniversity of Roma La SapienzaUnknown
-
Jazz PharmaceuticalsQuintiles, Inc.CompletedPain | Cancer | Palliative CareSpain, United Kingdom, United States, Canada, Poland, India, France, Czech Republic, Belgium, Romania, Chile, Finland, Germany, Italy, Mexico, South Africa
-
Jazz PharmaceuticalsCompleted
-
National Institute on Drug Abuse (NIDA)CompletedPharmacokinetics | Cannabis | Dependence | Cannabis Abuse | fMRIUnited States